bioMérieux

bioMérieux is a highly respected French multinational biotechnology company headquartered in Marcy-l’Étoile, France, and an undisputed global pioneer in the field of in vitro diagnostics (IVD), with a distinct, passionate focus on infectious diseases. Founded in 1963 by the historic Mérieux family, the company has grown into a cornerstone of global public health, resolutely dedicated to combating infectious threats and aggressively fighting the escalating global crisis of antimicrobial resistance (AMR) and sepsis.

bioMérieux provides a highly comprehensive suite of diagnostic solutions—including automated systems, proprietary reagents, and advanced informatics software—designed to rapidly and accurately determine the exact source of disease. The company completely dominates the clinical microbiology laboratory with its flagship automated platforms. This includes the VITEK® system for rapid pathogen identification and antimicrobial susceptibility testing (AST), and the BACT/ALERT® system for continuous, automated blood culture monitoring. In the rapidly evolving molecular diagnostics sphere, their groundbreaking BIOFIRE® syndromic testing platform has fundamentally revolutionized emergency medicine. By allowing clinicians to rapidly test for dozens of pathogens simultaneously from a single patient sample in about an hour, BIOFIRE® drastically accelerates targeted clinical interventions and saves lives.

Beyond its massive presence in clinical diagnostics, bioMérieux is also a dominant global player in industrial microbiology, actively ensuring the absolute safety, sterility, and quality of food, pharmaceutical, and cosmetic products worldwide. The company continually reinforces its technological leadership through strategic expansions, such as integrating advanced genomics, machine learning, and rapid flow cytometry capabilities to combat drug-resistant infections and support cell and gene therapy quality control. Through its unwavering commitment to continuous scientific innovation and global diagnostic accessibility, bioMérieux empowers clinicians and manufacturers alike to make critical, data-driven decisions that protect consumer safety and drastically improve patient health outcomes worldwide.